+ All Categories
Home > Documents > Joint Commission Blood Management Performance Measures

Joint Commission Blood Management Performance Measures

Date post: 31-Dec-2015
Category:
Upload: brenna-gilbert
View: 42 times
Download: 0 times
Share this document with a friend
Description:
Joint Commission Blood Management Performance Measures. Mark T. Lucas, MPS, CCP Joint Commission Technical Advisory Panel Blood Management Performance Measures Project. The Joint Commission. - PowerPoint PPT Presentation
Popular Tags:
55
Joint Commission Blood Management Performance Measures Mark T. Lucas, MPS, CCP Joint Commission Technical Advisory Panel Blood Management Performance Measures Project
Transcript
Page 1: Joint Commission Blood Management Performance Measures

Joint Commission Blood Management Performance

Measures

Mark T. Lucas, MPS, CCPJoint Commission Technical Advisory

Panel Blood Management Performance

Measures Project

Page 2: Joint Commission Blood Management Performance Measures
Page 3: Joint Commission Blood Management Performance Measures
Page 4: Joint Commission Blood Management Performance Measures
Page 5: Joint Commission Blood Management Performance Measures

The Joint Commission• "To continuously improve health care for the public, in

collaboration with other stakeholders, by evaluating health care organizations and inspiring them to excel in providing safe and effective care of the highest quality and value“

• The Joint Commission accredits over 19,000 health care organizations and programs in the United States.

• 400+ programs internationally.

• Centers for Medicare Services recognize Joint Commission accreditation as a condition of licensure and the receipt of Medicaid and Medicare reimbursement.

Page 6: Joint Commission Blood Management Performance Measures

History of The Joint Commission

• 1951 – ACP, AHA, AMA, CMA join with ACS to create the Joint Commission, an independent, not-for-profit organization whose primary purpose is to provide voluntary accreditation of hospitals on minimum standards for patient safety and efficacy of treatment.

• 1953 - JC published Standards for Hospital Accreditation

• 1965 – Congress passes the Social Security Amendments, stating that hospitals who meet JC standards can participate in Medicare and Medicaid programs.

Page 7: Joint Commission Blood Management Performance Measures

History of The Joint Commission

• 1995 – Federal Government recognizes Joint Commission laboratory accreditation services as meeting CLIA 1988 requirements.

• 1997 – JC introduces ORYX to integrate outcomes and performance measures into accreditation.

• 2003 National Patient Safety Goals are instituted.

• 2005 – JC goes global. WHO recognition.

Page 8: Joint Commission Blood Management Performance Measures

History of The Joint Commission

• 2007 – JC launches VAD Certification Program for destination therapy

• 2007 JC says “Hospitals go smoke free”

• 2007 Blood Management becomes important as a means of reducing unnecessary transfusions and costs

Page 9: Joint Commission Blood Management Performance Measures

JC is coming!!!!!

Page 10: Joint Commission Blood Management Performance Measures

The Joint Commission

Standardized performance measures NQF endorsed Inpatient hospital care Required for accreditation since 2002 Shared with Centers for Medicare & Medicaid

Services (mostly) Currently 10 sets More in development

Page 11: Joint Commission Blood Management Performance Measures

Performance Measures

Indicators, statistics, or metrics that are used to gauge the performance of an activity, process, or operating entity.

Performance measures are also the reference markers used to measure whether a goal is being achieved

• Patient decision-making based on data and scientific evidence.

• The results demonstrate improvements in health care quality and patient safety.

Page 12: Joint Commission Blood Management Performance Measures

12

Joint Commission Standards• Standards address the organization’s

level of performance in key functional areas

• Standards set forth performance expectations for activities that affect the safety and quality of patient care

• The Joint Commission develops its standards in consultation with health care experts, providers, measurement experts, purchasers, and consumers

Page 13: Joint Commission Blood Management Performance Measures

13

Transfusions in the United States

1. 80,000 transfusion decisions occur each day

2. U.S. txfs 44% more blood than Europe and Canada

3. Variability in txfsn practice, inadequate training in txfsn medicine, no standards for tx.

4. Rising costs of healthcare, blood products

5. New evidence for safety of blood txfsn

6. Importance and utility of blood management to reduce cost and promote effective use of resources

Page 14: Joint Commission Blood Management Performance Measures

Joint CommissionAll the variability in transfusion practices

shows "there is both excessive and inappropriate use of blood transfusions in the U.S.," advisers to Health and Human Services Secretary Kathleen Sebelius concluded earlier this month. "Improvements in rational use of blood have lagged."

Page 15: Joint Commission Blood Management Performance Measures

Stakeholder Panel Meeting -

February 5, 2007

• Stakeholders Meeting at Joint Commission in Chicago

• Feasibility and utility of developing a set of blood management performance measures

• Unrestricted educational grant from Bayer Healthcare Pharmaceuticals

Objectives: 1. Investigate the current state of blood management

practices 2. Review evidence-based studies, clinical guidelines and

performance measures for use in improving blood management practices

3. Establish the need and desire for standardized performance measures focused on blood management

Page 16: Joint Commission Blood Management Performance Measures

Stakeholder Organizations

• National Partnership for Women and Families• Society of Thoracic Surgeons• Cleveland Clinic• Department of Health and Human Services• American Academy of Orthopaedic Surgeons• American Association of Blood Banks• Food and Drug Administration• American College of Surgeons• American Society of Hematology• American Society of Anesthesiology• National Heart, Lung and Blood Institute• American Nurses Association• Society for Critical Care Medicine• American Red Cross• Society for the Advancement of Blood Management• Office of Blood Research and Review

Page 17: Joint Commission Blood Management Performance Measures

17

Technical Advisory Panel

•David J. Ballard, MD, MSPH, PhD, FACP, Co-chair•Neil Bangs, MS, MT (ASCP) SBB•Richard J. Benjamin, MD, PhD, FRCPath, MS•Laurence Bilfield, MD•Victor A. Ferraris, MD, PhD•John Freedman, MD, FPCPC•Jonathan C. Goldsmith, MD •Lawrence Tim Goodnough, MD•Penny S. Gozia, MD, MBA•Jerry Holmberg, PhD, MT (ASCP), SBB

•Jonathan H. Waters, MD, Co-chair•Harvey Klein, MD•Mark T. Lucas, MPS, RCS, CCP•Vijay K. Maker, MD, FACCS •John (Jeffrey) McCullough, MD•Aryeh Shander, MD, FCCM, FCCP•Bruce D. Spiess, MD, FAHA•Lynne, Uhl, MD•Jeffrey Wagner, BSN, RN•Rosalyn Yomatovian, MD

Page 18: Joint Commission Blood Management Performance Measures

The Gathering

Page 19: Joint Commission Blood Management Performance Measures

Panel Discussion

Page 20: Joint Commission Blood Management Performance Measures

PBM Development

Over 68 candidate measures considered by technical advisory panel (TAP)

19 measures selected for public comment10 measures underwent alpha testing7 measures selected for pilot testing

Page 21: Joint Commission Blood Management Performance Measures

21

Draft Measures for Alpha Testa

Transfusion indication

Transfusion consent

Blood administration documentation

Evaluation between multiple red blood cell transfusions

Timely emergency transfusions

Red blood cell administration

Prophylactic platelet administration

Plasma administration

Preoperative testing

Pretransfusion specimen rejections

a 8 of the measure populations would be determined based on medical record documentation of transfusion ICD-9-CM procedure codes (eg, 99.02, 99.04, etc).

Page 22: Joint Commission Blood Management Performance Measures

Final 7 Measures•BM-1 Informed Consent

•BM-2 RBC Transfusion Indication

•BM-3 Plasma Transfusion indication

•BM-4a Platelet Transfusion Indication

•BM-4b Prophylactic Platelet Transfusion Indication

•BM-5 Blood administration documentation

•BM-6 Preoperative Anemia Screening

•BM-7 Preoperative Blood Type Testing and Antibody Screening

Page 23: Joint Commission Blood Management Performance Measures

Transfusion Consent

• Numerator: Patients with a signed consent who received information about the risks, benefits and alternatives prior to the initial blood transfusion or the initial transfusion was deemed a medical emergency

• Denominator: Patients of all ages who received red blood cell, plasma or platelet transfusions

23

Page 24: Joint Commission Blood Management Performance Measures

Transfusion Consent Rationale

• The rate of transfusion consent in the US is unknown• Studies in other countries showed there is poor

documentation and room for improvement • Involving patients in healthcare decisions is a

national priority

24

Page 25: Joint Commission Blood Management Performance Measures

Transfusion Consent Data Elements

• Transfusion Consent

• Information Addressed Risks, Benefits and Alternatives to transfusion

25

Page 26: Joint Commission Blood Management Performance Measures

26

Transfusion Alternatives

• Preoperative Periodo Erythropoietino Androgenso Iron, folate, B12

supplements• Avoidance of anticoagulant drugs

o NSAIDSo Herbal supplementso Antiplatelet drugso Heparin/warfarin

• Intraoperative Periodo Normovolemic hemodilutiono Cell salvage

• Adjuncts o Point of care testingo Microsampling

• Drug therapyo desmopressino ε-aminocaproic acido recombinant factor VIIa

• Deliberate hypotension• Maintenance of normothermia• Avoidance of normal saline• Appropriate positioning

• Postoperative Periodo Washed or unwashed cell

salvageo Erythropoietin/Irono Hyperbaric oxygen therapyo Minimize phlebotomy

Page 27: Joint Commission Blood Management Performance Measures

27

RBC Transfusion Indication

N:Number of RBC transfusion units with pre-transfusion hemoglobin or hematocrit and clinical indication documented

D:Number of red blood cell transfusion units evaluated

Page 28: Joint Commission Blood Management Performance Measures

RBC Indication Rationale

• The rate of RBC transfusions in US hospitals is unknown

• Promotes a standardized process of:o checking a lab result prior to each transfusiono documentation of a reason why blood was

transfused• Information about total blood use could be used to

determine benchmarks by diagnoses or procedure

28

Page 29: Joint Commission Blood Management Performance Measures

RBC Data Elements

• Clinical Indication for RBCs• Pre-transfusion Hemoglobin/hematocrit Result• RBC ID

• Trauma patients excluded• RBC unit exclusions

29

Page 30: Joint Commission Blood Management Performance Measures

30

Plasma Transfusion Indication

N:Number of plasma transfusion units with pre-transfusion laboratory value AND clinical indication documented

D:Number of plasma units evaluated

Trauma patients excluded

Page 31: Joint Commission Blood Management Performance Measures

Plasma Rationale

• The rate of plasma transfused in the US hospitals is unknown

• Promotes a standardized process of:o checking a lab result prior to transfusiono documentation of a reason why blood was

transfused• STS recommends transfusion based on

bleeding and preferably guided by POC tests (Grade C, Class IIa)

31

Page 32: Joint Commission Blood Management Performance Measures

Plasma Data Elements

• Clinical Indication for Plasma

• Pre-transfusion Laboratory Testing

• Plasma ID

32

Page 33: Joint Commission Blood Management Performance Measures

33

Platelet Transfusion Indication

N:Number of platelet transfusion units with pre-transfusion platelet testing AND clinical indication documented

D:Number of platelet units evaluated

Trauma patients excluded

Page 34: Joint Commission Blood Management Performance Measures

Platelet Rationale

• The rate of platelets transfused in the US hospitals is unknown

• Transfusion of platelets associated with adverse events

• Promotes a standardized process of:o checking a lab result prior to transfusiono documentation of a reason why platelets

were transfused

34

Page 35: Joint Commission Blood Management Performance Measures

Platelet Data Elements

• Platelet Clinical Indication

• Pre-transfusion Platelet Testing

• Platelet ID

35

Page 36: Joint Commission Blood Management Performance Measures

36

Blood Administration Documentation

N:Number of transfusion units (bags) or doses with documentation for all of the following: o patient identification and transfusion order (or Blood

ID) confirmed prior to the initiation of transfusiono date and time of transfusion o blood pressure, (pulse) and temperature recorded

pre, during and post transfusion

D:Number of red blood cells, plasma and platelet units or doses evaluated

Page 37: Joint Commission Blood Management Performance Measures

Blood Administration Rationale

• Majority of blood is transfused in hospitals• Numerous errors are associated with

incorrect Patient ID• The transfusion process is very complex and

has been identified as a high-risk area for error

• Standardizing the process will enable reliable tracking of potential adverse events nationally

37

Page 38: Joint Commission Blood Management Performance Measures

Administration Data Elements

• Patient ID Verification • Transfusion Order• Transfusion Start Date• Transfusion Start Time• Vital Sign Monitoring• Blood ID Number

Note: Patients with trauma codes or RBC unit exclusions are not in this measure

38

Page 39: Joint Commission Blood Management Performance Measures

39

Preoperative Anemia Screening

N:Patients with preoperative anemia screening 14 - 45 days before Anesthesia Start Date

D:Selected elective surgical patients

Cardiac patients removed

Page 40: Joint Commission Blood Management Performance Measures

Anemia Screening Rationale

• Preoperative anemia is associated with increased morbidity and mortality

• A national audit found that 35% of patients scheduled for joint replacement therapy had a hgb <13 at preadmission testing

• Formal protocols for early detection, evaluation and management of high-blood loss surgeries has been identified as an unmet need

40

Page 41: Joint Commission Blood Management Performance Measures

Anemia Screening Data Elements

• Preoperative Anemia Screening Result Date

• Reasons for No Preoperative Anemia Screening

• Point of Origin for Admission or Visit

41

Page 42: Joint Commission Blood Management Performance Measures

42

Preoperative Blood Type Screening

N:Patients with preoperative type and screen or type and crossmatch completed prior to Surgery Start Time Anesthesia Start Time

D:Selected elective surgical patients

Page 43: Joint Commission Blood Management Performance Measures

Blood Type Testing Rationale

• This measure is supported by the Joint Commission National Patient Safety Goal

• Patient safety is a national priority

• This issue affects the majority of hospitals and other high-blood use procedures

43

Page 44: Joint Commission Blood Management Performance Measures

Blood Type Testing Data Elements

• Preoperative Blood Type Testing

• Blood Type Testing Ordered

44

Page 45: Joint Commission Blood Management Performance Measures

Lessons learned…• Measuring blood transfusions and associated

processes would enable hospitals to identify areas for improvement

• Optimizing a patient’s hemoglobin level before surgery may result in less blood use during and after surgery

• Checking to make sure blood is available before surgery (if ordered) is in the patient’s and hospital’s best interest

45

Page 46: Joint Commission Blood Management Performance Measures

Lessons learned…• These are general measures that collect data on

all patients that can be further analyzed by diagnoses and/or procedure code, age group or appropriateness as studies become available

• There is a lack of literature regarding “gaps in care” that these measures address

• The lack of national guidelines for blood – impacts the ability to standardize clinical indications

46

Page 47: Joint Commission Blood Management Performance Measures

Lessons learned…• The abstraction burden for these measures using

paper-based records is

• Complete data on all transfusions could be collected by eMeasures with minimal effort and provide comprehensive data on product usage and benchmarking

• Some of the measures are similar to the measures collected in Australia

47

Page 48: Joint Commission Blood Management Performance Measures

Final Lessons Learned…

• Use of these measures could be used in conjunction with the hemovigilance measures on transfusion related events

• If the rate of blood transfusions in hospitals is unknown, how will outcomes be monitored?

48

Page 49: Joint Commission Blood Management Performance Measures

Next Steps

• Measures have been placed in The Joint Commission’s Library of Other Measures for use by anyone interested

• Encourage use of the PBM measures at the local level

• Funding pending for retooling the specifications for retrieval from the electronic medical record

49

Page 50: Joint Commission Blood Management Performance Measures

PBM Data Collection

Page 51: Joint Commission Blood Management Performance Measures

PBM Data Collection

Page 52: Joint Commission Blood Management Performance Measures

National Quality Foundation

• NQF established a set of national voluntary consensus standards for measuring the quality of hospital care. These measures will permit consumers, providers, purchasers, and quality improvement professionals to evaluate and compare the quality of care in general acute care hospitals across the nation using a standard set of measures. The majority of the Joint Commission’s measures are endorsed by NQF and are denoted on the measure information forms.

• Final 7 measures were recommended by the TAP in November 2010 and submitted to the National Quality Forum (NQF) for consideration of endorsement in December 2010

• Not endorsed for use at the national level.

• Final measure specifications were posted in the Joint Commission Library of Other Measures in 2011. Measures that reside in the library are not collected, but are fully specified and available at the local level.

Page 53: Joint Commission Blood Management Performance Measures

Implementation Guide for The Joint

Commission Patient Blood Management

Performance Measures

• 180 page document• How to use and implement the measures• Measure interpretation, rationale,

responsible parties• ICD-9 relationship to measures• Data collection, documentation• Patient base• Algorithms for implementation• References, definitions, ICD-9 codes

Page 54: Joint Commission Blood Management Performance Measures

What Does This All Mean for

Perfusion

• Participating Hospitals will collect data on transfusion for appropriateness and cost effectiveness to compare with national standards

• New informed consent will mandate the explanation of transfusion alternatives, bringing about physician and patient knowledge and awareness of blood management

• Documentation and lab testing will be required, may increase costs

• Adoption of blood management will decrease costs and preserve resources

• Other agencies, CMS (?), may get on board

Page 55: Joint Commission Blood Management Performance Measures

Duh!!! Blood Management


Recommended